Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.53 billion, has been positioning itself for a new phase of multi-year growth ...

These growth stocks come from two very different industries. Eli Lilly is riding the GLP-1 drug wave, but there is much more ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...

Every generation seems to have an association with an illegal drug. Baby boomers had LSD, Gen X had pills and millennials had ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...